Wybrane najnowsze publikacje naszych autorów

• Voss M., Gurney H., Atduev V., Suarez C., Climent M., Pook D., Tomczak P., Barthélémy P., Lee J., Nalbandian T., Stus V., Ferguson T., Wiechno P., Gokmen E., Lacombe L., Gedye C., Cornell J., Sharma M., Burgents J., Albiges L.: First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial, European Urology, 2025,, DOI:10.1016/j.eururo.2025.05.019 , IF: 25.2
• Grignani G., Rutkowski P., Lebbé C., Guida M., Gaudy-Marqueste C., Spagnolo F., Burgess M., Morano F., Montaudié H., Depenni R., Spada F., Yeung C., Pulini J., Cornfeld M., Tian C., Bhatia S.: Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201), Journal for ImmunoTherapy of Cancer, BioMed Central, 2025, vol. 13, nr 8, nr art. e012478, DOI:10.1136/jitc-2025-012478, IF: 10.6
• Rychlik A., Kluz T., Szewczyk G., Coronado P., Łatkiewicz T., Tarkowski R., Woińska-Przekwas A., Nowosielski K., Skowronek K., Stojko R., Skuza M., Misiek M., Jabłoński K., Sadłecki P., Ciosek M., Pasicz K., Bogaczyk A., Bidziński M.: Real Life Evolution of Surgical Approaches in the Management of Endometrial Cancer in Poland, Cancers, 2025, vol. 17, nr 16, nr art. 2626, DOI:10.3390/cancers17162626, IF: 4.4
• Cao W., Kou F., Hu W., Hu L., Nie J., Dai L., Zhang J., Rui J., Knetki-Wróblewska M., Antonoff M., Fang J., Wang Y.: First-line immunotherapy in advanced non-squamous non-small cell lung cancer patients with rare mutations: a retrospective cohort study, Translational Lung Cancer Research, 2025, vol. 14, nr 7, s. 2788-2798, DOI:10.21037/tlcr-2025-716, IF: 3.5
• Chmiel P., Spałek M., Koseła-Paterczyk H., Rutkowski P., Jagodzińska-Mucha P., Rogala P., Kozak K., Telejko M., Borkowska A.: Efficacy of radiotherapy and radiotherapy with hyperthermia to delay change of systemic therapy in patients with metastatic melanoma, Clinical and Translational Radiation Oncology, 2025, vol. 55, nr art. 101024, DOI:10.1016/j.ctro.2025.101024, IF: 2.7